Over 25,000 Study Participants Received a 2nd COVID-19 Vaccine Dose

Massachusetts based Moderna, Inc. announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE study of the mRNA-1273 vaccine candidate against COVID-19. As of October 22, 2020, more than 25,650 participants have received their 2nd vaccination.